NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
NiKang Enters into Clinical Trial Collaboration Agreement to Evaluate NKT2152
NiKang Therapeutics, a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, announced that Dr. Anne E. Borgman has been appointed to the company’s Board of Directors.
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, 3692.HK), a China and US based leading biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs today announced presentation of preclinical data investigating NKT2152’s mechanism of action, in vivo pharmacokinetic and pharmacodynamic profile, and anti-tumor effect in multiple xenograft models including ccRCC and hepatocellular carcinoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.
WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang’s small molecule that inhibits hypoxia inducible factor 2? (HIF2?), in combination with FOTIVDA® (tivozanib), AVEO’s oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. The phase 2 clinical trial will evaluate the safety and efficacy of the combination of NKT2152 and tivozanib in clear cell RCC (ccRCC) patients who have not responded to or relapsed from prior therapies (R/R RCC). Under the terms of the agreement, NiKang will sponsor the trial and AVEO will co- fund the trial. Both companies will provide its respective drugs at no cost. The two companies will form a Joint Development Committee to oversee this collaboration.
WILMINGTON, Del.--(BUSINESS WIRE)--NiKangnTherapeutics Inc. (“NiKang”), a clinical stage biotech company focused non developing innovative small molecule oncology medicines to help npatients with unmet medical needs, today announced that the first npatient has been dosed in a phase 1/2, open-label, dose escalation and nexpansion study of single agent NKT2152, a small molecule that inhibits nhypoxia inducible factor 2? (HIF2?). HIF2? is a transcription factor nimplicated in the development and progression of cancer including clear ncell renal cell carcinoma (ccRCC).
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that the first patient has been dosed in a phase 1/2, open-label, dose escalation and expansion study of single agent NKT2152, a small molecule that inhibits hypoxia inducible factor 2? (HIF2?). HIF2? is a transcription factor implicated in the development and progression of cancer including clear cell renal cell carcinoma (ccRCC).